

Claims

1. An antagonist of a Programmed Death Ligand 1 protein (PD-L1) and a VEGFR inhibitor for use as a medicament in the treatment of a cancer in a subject; or
 a PD-L1 antagonist for use as a medicament in the treatment of a cancer in a subject, wherein the PD-L1 antagonist is for use in combination with a VEGFR inhibitor in the form of a medicament; or
 a VEGFR inhibitor for use as a medicament in the treatment of a cancer in a subject, wherein the VEGFR inhibitor is for use in combination with a PD-L1 antagonist in the form of a medicament;

wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs from a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 8, and three CDRs from a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 9, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide or a pharmaceutically acceptable salt thereof.

2. Use of:

a) an antagonist of a Programmed Death Ligand 1 protein (PD-L1) and a VEGFR inhibitor in the manufacture of a medicament for the treatment of a cancer in a subject; or
 b) an antagonist of a Programmed Death Ligand 1 protein (PD-L1) in the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is for use in combination with a VEGFR inhibitor in the form of a medicament; or
 c) a VEGFR inhibitor in the manufacture of a medicament for the treatment of a cancer in a subject, wherein the medicament is for use in combination with a PD-L1 antagonist in the form of a medicament;

and wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs from a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 8, and three CDRs from a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 9, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide or a pharmaceutically acceptable salt thereof.

3. The use of claim 2, wherein the subject is a human.
4. The use of claim 2 or claim 3, wherein the cancer is a solid tumor.
5. The use of claim 4, wherein the tumor tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.
6. The use of claim 2 or claim 3, wherein the cancer is renal cell carcinoma.
7. The use of any one of claims 2 to 6, wherein the PD-L1 antagonist is avelumab and the VEGFR inhibitor is axitinib.
8. The use of any one of claims 2 to 7, wherein the PD-L1 antagonist is to be administered as an initial dose of at least about 5 mg/kg, or about 10 mg/kg; and the VEGFR inhibitor is to be administered as an initial dose of at least 3 mg/kg or 5 mg/kg.
9. The use of any one of claims 2 to 8, wherein the PD-L1 antagonist is to be administered about once a week, or about once every two, three, four, or five weeks; and the VEGFR inhibitor is to be administered twice daily.
10. The use of claim 9, wherein the PD-L1 antagonist is to be administered about once every two weeks; and the VEGFR inhibitor is to be administered twice daily.
11. The use of claim 7, wherein the avelumab is formulated as a liquid medicament and axitinib is formulated as a 1 mg tablet, a 3 mg tablet, or a 5 mg tablet.
12. Use of a kit including:
 - i) a first container comprising at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-L1);
 - ii) a second container comprising at least one dose of a medicament comprising a VEGFR inhibitor; and
 - iii) a package insert comprising instructions to treat a subject for cancer using the medicaments;in the manufacture of a medicament for the treatment of cancer in a subject,

wherein the PD-L1 antagonist is an anti-PD-L1 monoclonal antibody comprising three CDRs from a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 8 and three CDRs from a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 9, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-inda-zol-6-ylsulfanyl]benzamide or a pharmaceutically acceptable salt thereof.

13. The use of claim 12, wherein the instructions state that the medicaments are intended for use in treating a subject having a cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

14. The use of claim 12 or claim 13, wherein the subject is a human.

15. The use of any one of claims 12 or claim 13, wherein the PD-L1 antagonist is avelumab formulated as a liquid medicament and the VEGFR inhibitor is axitinib formulated as a 1 mg tablet or a 5 mg tablet.

16. The use of any one of claims 2-15, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B- cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), or small lymphocytic lymphoma (SLL).

17. The use of any one of claims 1 to 15, wherein the cancer is advanced renal cell carcinoma.

18. The use of claim 17, wherein the renal cell carcinoma is previously untreated advanced renal cell carcinoma.